Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone Combo With Humalog Mix25 and With Simultaneous Injections of Humalog and Lantus in Subjects With Type 2 Diabetes

Next Previous
Trial Profile

A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone Combo With Humalog Mix25 and With Simultaneous Injections of Humalog and Lantus in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine/insulin lispro (Primary) ; Insulin glargine; Insulin lispro; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Adocia

Most Recent Events

  • 16 Sep 2016 Results assessing pharmacodynamic profile of BioChaperone Combo, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
  • 08 Sep 2016 According to an Adocia media release, data from this trial were presented at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 2016.
  • 06 Jun 2016 Data will be presented at the American Diabetes Association 76th Scientific Sessions 2016, according to an Adocia media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top